Therapeutic Antibody Evaluation Services
The JAX Therapeutic Antibody Evaluation Services rely on a unique humanized mouse collection. Using its humanized FcRn models to deliver accurate data and get therapeutic candidates into the clinic—and ultimately in the hands of physicians and patients—faster.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
From preclinical to clinical: get relevant translational and fast half-life comparison data
The Jackson Laboratory evaluates the in vivo stability of therapeutic antibodies and other Fc-based biologics using its unique platform consisting of humanized mouse models that are deficient in murine FcRn and express human FcRn at different levels. Developed by JAX professor Derry Roopenian, Ph.D., these mice allow for:
- Generation of faster, predicative clinically-relevant data for antibody stability
- Effective and proven alternative to non-human primates,
- Preclinical pharmacokinetic (PK) analysis of Fc-domain based therapeutic candidates
- Cost effectiveness, since they require only small quantities of a given molecule
- Testing of any kind of Fc-domain albumin-conjugate, or therapeutic carried by albumin used in immuno-oncology and autoimmune research, among others
The humanized mouse platform: Description of the most used models
- B6.Cg-Fcgrttm1Dcr Tg(FCGRT)32Dcr/DcrJ (014565) mice have a null mutation for the mouse gene and a transgene expressing the human FcRn under the endogenous promoter (hTg32). These mice have the highest, most human-like protection of humanized IgG and are the best model for use when maximum half-life data is required
- B6.Cg-Fcgrttm1Dcr Tg(CAG-FCGRT)276Dcr/DcrJ (004919) mice carry a null mutation for the mouse gene and a transgene expressing human FcRn. Mice hemizygous for the human FcRn transgene (hTg276) are best suited to detect subtle differences in antibody persistence in vivo
- B6.Cg-Fcgrttm1Dcr Prkdcscid Tg(FCGRT)32Dcr/DcrJ (018441) mice express the hTg32 transgene and are immunodeficient. These mice have the highest, most human-like protection of humanized IgG and are useful in evaluating Fc-domain based therapeutics that are potentially immunogenic or involve xenografts
- B6.Cg-Albem12Mvw Fcgrttm1Dcr Tg(FCGRT)32Dcr/MvwJ (025201) albumin knockout hTg32 mice are an effective, human-like model for characterization of the pharmacokinetics of albumin-conjugates, or therapeutics carried by albumin
Humanized mice bring translationally relevant results with JAX preclinical services
Humanized mice are emerging as essential preclinical in vivo tools to accelerate successful drug development. Their utility lies in their ability to reliably recapitulate human physiology and pathophysiology and predict critical aspects of the human response to immunomodulatory compounds. These models provide drug developers the insights needed to identify problematic compounds and fine-tune lead candidates to confidently advance to the clinic.
In this SelectScience webinar, Dr. Kaya Ghosh, Technical Information Scientist, and Dr. Aaron Rose, senior study director, data analytics and visualization for preclinical services, at The Jackson Laboratory (JAX) share how the company is committed to developing and providing access to humanized mouse models and in vivo drug development services that use humanized mice. Practical examples of humanized mouse model utility and how they are reshaping the biologic drug development pipeline will also be covered.
Key learning objectives
- Learn about genetically and immune humanized mice
- Understand why humanized mice bridge the preclinical-clinical gap better than conventional models
- Discover how JAX’s in vivo Preclinical Research Services can help de-risk drug development and therapeutics into the clinic faster
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Read more on how humanized mice are reshaping the biologic drug development pipeline >>
How FcRn mouse models from JAX reveal antibody half-life and stability
Advancing clinical pharmacokinetic prediction beyond non-human primate models
Translatable efficacy & safety testing of mAb, bispecific, & CAR T therapies
Watch this on-demand webinar to learn about monoclonal antibody-based human immune modulation in enhancing therapeutic outcomes
Mouse models yield translational pharmacokinetic data for Fc-based therapeutics
Greg Christianson, Study Director for In Vivo Services at The Jackson Laboratory, explores the range of human FcRn mouse models available for providing preclinical assessment to gain translational pharmacokinetic data
